TORONTO, Nov. 05, 2025 (GLOBE NEWSWIRE) -- Arch Biopartners Inc. (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF) announced today that the Fraser Health Research Ethics Board (“REB”) has granted approval for the Royal Columbian Hospital (RCH) to participate in Arch’s ongoing Phase II trial evaluating LSALT peptide for the prevention and treatment of cardiac surgery-associated acute kidney injury (CS-AKI). With this ethics approval in place, the clinical team at RCH in New Westminster, British Columbia, will proceed to complete operational approvals, training, and site initiation prior to ...

• Arch acquires a new CKD platform that has the potential to produce next-generation CKD drugs for the pharmaceutical industry

• Based on a novel mechanism of action involving IL-32 and directly implicated in CKD, discovered in pre-clinical studies led by Dr. Justin Chun

• The Company has filed both composition and method of use patents relating to the CKD platform.

• The Arch CKD program will be led by Dr. Justin Chun, who joins the Company as a Principal Scientist

• CKD is largely an unmet medical need, currently affecting more than 800 million people ...
  
  Full Release

• First patient successfully completes dosing at Toronto General Hospital
• St. Michael’s Hospital is expected to be the next Canadian clinical site activated
• Arch is looking for additional clinical sites in North America to join the trial

TORONTO, Aug. 06, 2025 (GLOBE NEWSWIRE) -- Arch Biopartners Inc. (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF) announced today that the first patient has successfully completed dosing at Toronto General Hospital (TGH), part of the University Health Network (UHN), Canada’s largest academic health sciences centre and a global leader in cardiac care and research ...